Advancing precision drug through innovative chemistry and advanced molecular technologies.
Integrated CDMO services spanning discovery, process development, custom synthesis and commercial manufacturing.
Delivering reliable CDMO solutions for innovative therapeutics worldwide.
고도화된 화학 프로젝트를 위한 유기 합성, 맞춤 합성, 공정 개발 및 스케일업 지원.
복잡한 분자를 위한 합성 및 분석 기술.
CHEMOS는 합성 중심 CDMO로서 유기 합성, 맞춤 합성, 경로 개발, 공정 개발, 스케일업 지원 및 분석 지원에 집중합니다.
CHEMOS의 뉴스, 인사이트 및 업데이트.
FDA announced on July 16, 2026 that Lipfendra (enlicitide) was approved to be used with diet and exercise to reduce LDL-C in adults with high cholesterol or heterozygous familial hypercholesterolemia. FDA also states that Lipfendra is a tablet taken by mouth once daily and is the first oral therapy that blocks PCSK9.
더 보기The key correction is that the ACS Organic Process Research & Development paper describes LUNA18 (paluratide) through a liquid-phase peptide synthesis process, not a simple SPPS plus three-fragment route. The paper’s abstract says the authors departed from conventional solid-phase peptide synthesis and developed an LPPS process for an N-alkyl-rich cyclic undecapeptide KRAS inhibitor.
더 보기
The reported inclisiran architecture illustrates why an siRNA conjugate cannot be reduced to a sequence plus a targeting ligand. Descriptions of that architecture place a triantennary N-acetylgalactosamine (GalNAc) unit at the sense-strand terminus, combine 2'-fluoro and 2'-O-methyl ribose substitutions with terminal phosphorothioate linkages, and rely on the antisense strand for RNA-induced silencing complex (RISC) loading. Each element addresses a different constraint: cell uptake, nuclease exposure, strand handling, or intracellular recognition.
초기 경로 평가부터 공정 개발 및 스케일업까지 CHEMOS는 R&D 경험과 생산 기반으로 맞춤 합성을 지원합니다.
